Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sti-9167 save search
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)
Published: 2022-10-14 (Crawled : 19:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
| Email alert
Add to watchlist
sti-9167 preclinical antibody sars-cov-2 publication
Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD™ IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.0%
H: 8.61%
C: 7.28%
sti-9199 antibody enroll
Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
Published: 2022-04-25 (Crawled : 14:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.0%
H: 5.26%
C: 2.92%
sti-9167 fda antibody sars-cov-2 authorization phase 1
Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
sti-9199 covid-19 fda covid phase 1 authorization antibody
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
Published: 2022-03-02 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
sti-9199 sars-cov-2 drop antibody infection infections
Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses
Published: 2022-02-22 (Crawled : 18:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.75%
H: 3.39%
C: -0.71%
sti-9167 antibody
SORRENTO THERAPEUTICS ANNOUNCES COVISHIELD (STI-9167), A BROAD-SPECTRUM NEUTRALIZING ANTIBODY, POTENTLY NEUTRALIZES OMICRON AND OMICRON (+R346K) VARIANTS OF SARS-COV-2
Published: 2022-01-20 (Crawled : 19:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.47%
H: 5.59%
C: -2.8%
sti-9167 therapeutics sars-cov-2 antibody
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.